iCAD Showcases Advanced AI Solutions for Breast Cancer Detection at SABCS and RSNA 2024

Curated by THEOUTPOST

On Thu, 5 Dec, 8:03 AM UTC

4 Sources

Share

iCAD presents groundbreaking AI-driven breast cancer research at SABCS 2024 and unveils new partnerships and FDA-cleared technologies at RSNA 2024, advancing early detection and risk assessment across diverse populations.

iCAD Presents Groundbreaking AI Research at SABCS 2024

iCAD, Inc. (NASDAQ: ICAD), a leader in AI-powered cancer detection solutions, announced the presentation of four novel AI-driven breast cancer research abstracts at the 2024 San Antonio Breast Cancer Symposium (SABCS) 1. The research focuses on improving detection and risk prediction accuracy while assessing disparities across diverse populations.

Key Research Findings

Three research abstracts presented by Dr. Chirag R. Parghi, Chief Medical Officer at Solis Mammography, highlight significant advancements:

  1. An AI algorithm for identifying Breast Arterial Calcifications (BAC) showed that BAC prevalence increases with age but doesn't vary by race, suggesting its potential as a universal cardiovascular biomarker 1.

  2. An AI-driven short-term breast cancer risk assessment score demonstrated effectiveness across race and breast density, potentially addressing gaps in traditional mammography 1.

  3. AI-based mammographic case scoring showed consistency across different racial and breast density groups, indicating potential for more equitable screening results 1.

Additionally, Dr. Mikael Eriksson from Karolinska Institute presented research on a 10-year image-derived AI-risk model based on iCAD's ProFound Risk solution, which outperformed the clinical Tyrer-Cuzick v8 risk model 1.

iCAD's Advancements at RSNA 2024

At the Radiological Society of North America (RSNA) 2024 Annual Meeting, iCAD showcased its latest breast health AI technologies 2:

  1. FDA-cleared ProFound Detection Version 4: This next-generation AI solution incorporates prior exams into current analysis, improving aggressive cancer detection by 22% and reducing cases with no marks by 18% 2.

  2. Partnership with Cascaid Health: The collaboration will launch ProFound Health, a virtual care model enabling women to access AI-powered breast health services. This initiative aims to democratize access to advanced breast health technology 2.

Impact on Breast Cancer Detection

Dr. Kathy Schilling, Medical Director at Boca Raton Regional Hospital, reported significant improvements in cancer detection rates after integrating ProFound AI:

  • 23% overall increase in cancer detection rates
  • 4% rise in invasive cancer detection
  • Doubled rates of lobular cancer detection 4

These advancements address critical gaps in breast cancer screening, particularly for women with dense breast tissue, where traditional mammography often falls short 2.

Future Implications

The research and technological advancements presented by iCAD at SABCS and RSNA 2024 demonstrate the potential of AI to revolutionize breast cancer detection and risk assessment. By providing more accurate, consistent, and equitable screening results across diverse populations, these AI solutions could significantly improve early detection rates and patient outcomes in breast cancer care.

Continue Reading
iCAD and Cascaid Health Partner to Revolutionize Breast

iCAD and Cascaid Health Partner to Revolutionize Breast Cancer Detection with AI-Powered Solutions

iCAD, Inc. showcases groundbreaking AI technologies for breast health at RSNA 2024, including FDA-cleared ProFound Detection Version 4 and a new partnership with Cascaid Health to expand access to AI-driven breast health solutions.

Investing.com UK logoBenzinga logo

2 Sources

Investing.com UK logoBenzinga logo

2 Sources

iCAD Announces Q3 2024 Financial Results Release and

iCAD Announces Q3 2024 Financial Results Release and Participation in Craig-Hallum Conference

iCAD, a leader in AI-powered cancer detection, sets date for Q3 2024 financial results and plans to attend the Craig-Hallum Alpha Select Conference, showcasing its commitment to AI innovation in healthcare.

Investing.com UK logoBenzinga logo

2 Sources

Investing.com UK logoBenzinga logo

2 Sources

iCAD to Present at iAccess Alpha Buyside Best Ideas Fall

iCAD to Present at iAccess Alpha Buyside Best Ideas Fall Conference 2024

iCAD, Inc., a global medical technology leader in cancer detection and therapy solutions, announces its participation in the upcoming iAccess Alpha Buyside Best Ideas Fall Conference 2024. The company's CEO, Stacey Stevens, will deliver a virtual presentation on September 12, 2023.

Investing.com UK logoBenzinga logo

2 Sources

Investing.com UK logoBenzinga logo

2 Sources

Q2 2024 Financial Results: A Mixed Bag for Tech and

Q2 2024 Financial Results: A Mixed Bag for Tech and Healthcare Companies

Several companies, including iCAD, SKYX, Acrivon Therapeutics, and Janover, have reported their second quarter 2024 financial results. While some companies showed growth, others faced challenges in revenue and net losses.

Investing.com UK logoBenzinga logo

6 Sources

Investing.com UK logoBenzinga logo

6 Sources

RadNet's DeepHealth Unveils AI-Powered Innovations in

RadNet's DeepHealth Unveils AI-Powered Innovations in Medical Imaging at RSNA 2024

DeepHealth, a RadNet subsidiary, launches new AI-powered solutions for medical imaging at RSNA 2024, including SmartTechnology™ innovations and collaborations with industry leaders to improve healthcare efficiency and patient care.

Investing.com UK logoBenzinga logoMarket Screener logo

13 Sources

Investing.com UK logoBenzinga logoMarket Screener logo

13 Sources

TheOutpost.ai

Your one-stop AI hub

The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.

© 2025 TheOutpost.AI All rights reserved